Harrow re-launches Verkazia to target rare pediatric eye disease market

Harrow (NASDAQ:HROW) announced the formal commercial re-launch of Verkazia, a targeted prescription therapy for vernal keratoconjunctivitis (VKC), an underdiagnosed but severe chronic allergic eye disease that primarily affects children.

The strategic roll-out marks the second of three high-priority product activations planned within the Nashville-based eyecare company’s current portfolio strategy.

According to management, the primary roadblock historically hindering Verkazia has not been its clinical efficacy, but rather consistent market access and distribution reliability.

The new initiative will deploy a commercial structure designed to stabilize supply lines, educate clinicians, and lower procurement barriers for patients.

VKC is an inflammatory ocular condition that can lead to severe itching, pain, light sensitivity, and eventual corneal damage if left unmanaged.

While standard antihistamines fail to control symptoms in roughly 61% of patients, clinicians have frequently relied on heavy courses of corticosteroids to manage flare-ups.

However, prolonged steroid therapy in pediatric demographics carries severe long-term risks, including the development of cataracts and glaucoma.

Verkazia, a topical calcineurin inhibitor immunomodulator, functions as a 0.1% cyclosporine ophthalmic emulsion that isolates the underlying immune responses causing the inflammation.

Because it manages the chronic disease pathway without the structural complications introduced by topical steroids, medical consensus increasingly supports early intervention with calcineurin inhibitors to protect long-term visual acuity in children.